These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 20838345)

  • 1. Cardiovascular aspects of antipsychotics.
    Raedler TJ
    Curr Opin Psychiatry; 2010 Nov; 23(6):574-81. PubMed ID: 20838345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular effects of antipsychotics.
    Michelsen JW; Meyer JM
    Expert Rev Neurother; 2007 Jul; 7(7):829-39. PubMed ID: 17610390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia.
    Casey DE; Haupt DW; Newcomer JW; Henderson DC; Sernyak MJ; Davidson M; Lindenmayer JP; Manoukian SV; Banerji MA; Lebovitz HE; Hennekens CH
    J Clin Psychiatry; 2004; 65 Suppl 7():4-18; quiz 19-20. PubMed ID: 15151456
    [No Abstract]   [Full Text] [Related]  

  • 4. Atypical antipsychotics: enhancing healthy outcomes.
    Casey DE
    Arch Psychiatr Nurs; 2002 Jun; 16(3 Suppl 1):S12-9. PubMed ID: 12046020
    [No Abstract]   [Full Text] [Related]  

  • 5. Cardiovascular risks of atypical antipsychotic drug treatment.
    Drici MD; Priori S
    Pharmacoepidemiol Drug Saf; 2007 Aug; 16(8):882-90. PubMed ID: 17563919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of schizophrenia with obesity, metabolic, and endocrinological disorders.
    Monteleone P; Martiadis V; Maj M
    Psychiatr Clin North Am; 2009 Dec; 32(4):775-94. PubMed ID: 19944883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serious cardiovascular events and mortality among patients with schizophrenia.
    Enger C; Weatherby L; Reynolds RF; Glasser DB; Walker AM
    J Nerv Ment Dis; 2004 Jan; 192(1):19-27. PubMed ID: 14718772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Metabolic risk during antipsychotic treatment in patients with schizophrenia].
    Rzewuska M
    Psychiatr Pol; 2007; 41(4):457-72. PubMed ID: 18046977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic complications of schizophrenia and antipsychotic medications--an updated review.
    Yogaratnam J; Biswas N; Vadivel R; Jacob R
    East Asian Arch Psychiatry; 2013 Mar; 23(1):21-8. PubMed ID: 23535629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder.
    McIntyre RS; Konarski JZ
    J Clin Psychiatry; 2005; 66 Suppl 3():28-36. PubMed ID: 15762832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of cardiovascular disease and sudden death in schizophrenia.
    Davidson M
    J Clin Psychiatry; 2002; 63 Suppl 9():5-11. PubMed ID: 12088174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antipsychotic medications: metabolic and cardiovascular risk.
    Newcomer JW
    J Clin Psychiatry; 2007; 68 Suppl 4():8-13. PubMed ID: 17539694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing cardiovascular risks versus clinical benefits of atypical antipsychotic drug treatment.
    Meltzer HY; Davidson M; Glassman AH; Vieweg WV
    J Clin Psychiatry; 2002; 63 Suppl 9():25-9. PubMed ID: 12088173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Which comes first: atypical antipsychotic treatment or cardiometabolic risk?
    Stahl SM; Mignon L; Meyer JM
    Acta Psychiatr Scand; 2009 Mar; 119(3):171-9. PubMed ID: 19178394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Life expectancy and cardiovascular mortality in persons with schizophrenia.
    Laursen TM; Munk-Olsen T; Vestergaard M
    Curr Opin Psychiatry; 2012 Mar; 25(2):83-8. PubMed ID: 22249081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of clozapine safety.
    Fitzsimons J; Berk M; Lambert T; Bourin M; Dodd S
    Expert Opin Drug Saf; 2005 Jul; 4(4):731-44. PubMed ID: 16011451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence.
    Newcomer JW
    J Clin Psychiatry; 2007; 68 Suppl 1():20-7. PubMed ID: 17286524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperglycemia and antipsychotic medications.
    Haupt DW; Newcomer JW
    J Clin Psychiatry; 2001; 62 Suppl 27():15-26; discussion 40-1. PubMed ID: 11806485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Response to the position of the "Biological Psychiatry" Working Group of the Federal Directors Conference--Association of Executive Physicians of Psychiatry and Psychotherapy Clinics (BDK) e.V].
    Aderhold V
    Psychiatr Prax; 2009 Mar; 36(2):94-5. PubMed ID: 19358097
    [No Abstract]   [Full Text] [Related]  

  • 20. Cardiovascular disease in patients with schizophrenia.
    Kritharides L; Chow V; Lambert TJ
    Med J Aust; 2017 Feb; 206(2):91-95. PubMed ID: 28152356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.